Article
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
Haematologica - 1 Jan 2017
Gupta Vikas, Mesa Ruben A, Deininger Michael W N, Rivera Candido E, Sirhan Shireen, Brachmann Carrie Baker, Collins Helen, Kawashima Jun, Xin Yan, Verstovsek Srdan
Abstract excerpt
Momelotinib, a small-molecule inhibitor of Janus kinase 1 and Janus kinase 2, has demonstrated efficacy in myelofibrosis patients with 300 mg, once-daily dosing. This open-label, non-randomized, phase 1/2 study evaluated the safety and therapeutic benefit of momelotinib with twice-daily dosing. A total of 61 subjects with primary myelofibrosis or post-polycythemia vera/post-essential thrombocythemia myelofibrosis...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.